Given the range of potent effector pathways available to NeoAg-specific CD4+ T cells for the control of incipient cancers, the progressive outgrowth of primary and metastatic tumors suggests that these either do not develop or are actively suppressed under physiologic conditions. This evidence concerns the gene CD4 and cancer.